Readers are invited to write in with their questions about decisions of the Pharmaceutical Benefits Advisory Committee (PBAC). Australian Prescriber publishes selected questions from readers, together with answers from the PBAC. Questions may address issues such as regulatory decisions, pharmaceutical benefits listings and withdrawals.
This exclusive arrangement helps Australian Prescriber readers understand how the contents of the Pharmaceutical Benefits Scheme (PBS) are determined.
Letters and responses are reviewed by the Editorial Executive Committee and may be edited before publication. It may not be possible to reply to all individual questions.
One of the letters published in 'Your questions to the PBAC' (Aust Prescr 2001;24:7) mentioned celecoxib as a general benefit on the Pharmaceutical Benefits Scheme (PBS). This is incorrect. Celecoxib is listed on the PBS as a restricted benefit for chronic arthropathies (including osteoarthritis) with an inflammatory component.